Dishman Pharma gets EIRs for 3 sites from USFDA
New Delhi : Dishman Pharmaceuticals and Chemicals has received Establishment Inspection Report from the US health regulator for three of its facilities.
"Company's wholly owned subsidiary Carbogen Amcis AG, Switzerland has successfully completed United States Food and Drug Administration (USFDA) inspection for its two sites located at Aarau and Neuland without any adverse observations," Dishman Pharmaceuticals and Chemicals said in a BSE filing.
It has received the Establishment Inspection Report (EIR) for the same, it added.
"Now the company has the above two sites in addition to Bubendorf in Switzerland, which are approved by the USFDA, Dishman said.
The company's site at Naroda has also completed successful USFDA inspection and received EIR for the same, the company added.
Shares of Dishman Pharmaceuticals and Chemicals today closed 2.66 per cent up at Rs 136.85 per scrip on BSE.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd